Alterity Therapeutics Ltd Share Price Australian S.E.
Stocks
AU000000PBT9
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 75.22M 64.69M 61.03M 55.6M 104M 7.19B 105M 727M 280M 3.65B 282M 276M 11.59B | P/E 2027 * |
-4.8x | P/E 2028 * | -0.28x |
|---|---|---|---|---|---|
| Enterprise Value | 34.31M 29.51M 27.84M 25.36M 47.42M 3.28B 47.85M 332M 128M 1.66B 129M 126M 5.29B | EV / Sales 2027 * |
60.1x | EV / Sales 2028 * | 16.5x |
| Free-Float |
93.14% | Yield 2027 * |
-
| Yield 2028 * | - |
Last Transcript : Alterity Therapeutics Ltd
| 1 day | +2.04% |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 06/01/2021 |
| Director of Finance/CFO | - | 29/09/2024 | |
| Chief Tech/Sci/R&D Officer | - | 31/03/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 28/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 07/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 20/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.04% | +2.08% | - | - | 75.22M | |
| +0.13% | -5.54% | -4.05% | +9.98% | 46.05B | |
| -2.08% | -3.57% | +402.72% | +533.09% | 43.59B | |
| +0.12% | -5.27% | +39.94% | +20.50% | 42.35B | |
| -2.62% | -5.76% | +8.88% | +77.44% | 38.86B | |
| -1.26% | -3.37% | +11.87% | +40.55% | 32.24B | |
| +0.16% | -3.65% | - | - | 17.16B | |
| -0.54% | -1.72% | +22.34% | +115.10% | 16.28B | |
| +0.25% | -2.20% | +11.12% | +31.27% | 14.32B | |
| -1.92% | -6.94% | +78.12% | +36.68% | 13.03B | |
| Average | -0.57% | -4.70% | +71.37% | +108.07% | 29.32B | |
| Weighted average by Cap. | -0.94% | -5.04% | +86.44% | +128.40% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 571K 491K 463K 422K 788K 54.55M 796K 5.51M 2.12M 27.67M 2.14M 2.1M 87.88M | 2.31M 1.98M 1.87M 1.71M 3.19M 221M 3.22M 22.3M 8.58M 112M 8.67M 8.48M 356M |
| Net income | -26.81M -23.06M -21.75M -19.82M -37.04M -2.56B -37.38M -259M -99.71M -1.3B -101M -98.47M -4.13B | -29.79M -25.62M -24.18M -22.02M -41.17M -2.85B -41.54M -288M -111M -1.44B -112M -109M -4.59B |
| Net Debt | -40.9M -35.18M -33.19M -30.24M -56.52M -3.91B -57.03M -395M -152M -1.98B -154M -150M -6.3B | -37.15M -31.95M -30.15M -27.46M -51.34M -3.55B -51.8M -359M -138M -1.8B -140M -136M -5.72B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
